Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cannabinoid therapeutics - Emerald/VivaCell

Next Previous
Drug Profile

Research programme: cannabinoid therapeutics - Emerald/VivaCell

Alternative Names: APH-1305; Neurodegenerative disease therapeutics - Aphios Corporation/VivaCell Biotechnology Espana; VCE-003; VCE-003.1; Δ9 Tetrahydrocannabinoid; Δ9 THCA

Latest Information Update: 28 Oct 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphios Corporation; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
  • Developer Aphios Corporation; Emerald Health Sciences; Universidad Nacional de Cordoba; VivaCell Biotechnology Espana
  • Class Cannabinoids; Quinones
  • Mechanism of Action Cannabinoid receptor CB2 agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • No development reported Fibrosis; Multiple sclerosis; Scleroderma

Most Recent Events

  • 28 Oct 2020 No recent reports of development identified for preclinical development in Fibrosis in Spain (PO)
  • 28 Oct 2020 No recent reports of development identified for preclinical development in Scleroderma in Spain (PO)
  • 28 Sep 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis in Spain (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top